Stand Up To Cancer has launched two initiatives to increase minority representation in cancer clinical trials by amending its grant application requirements and funding a new research team focused on diversity and inclusion.
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
